Summary:
A randomized, double-blind, placebo-controlled dose-escalation study to determine the safety and efficacy of intravenous infusion of human placenta-derived cells (pda001) for the treatment of Crohn’s Disease.
Might be Eligible If:
- Male or Female, 18 - 75 years of age
- Crohn's Disease (CD) diagnosed at least 6 months but no greater than 10 years
Not Eligible If:
- Pregnant or lactating females
Note: Full eligibility requirements can be discussed with a physician at one of the study locations.